Evidence map›Paper›PMID 15133865›Full record

Trial reportWorld journal of gastroenterology2004

Effects of probiotic on intestinal mucosa of patients with ulcerative colitis.

Hai-Hong Cui, Cun-Long Chen, Ji-De Wang, Yu-Jie Yang, Yong Cun, Jin-Bao Wu, Yu-Hu Liu, Han-Lei Dan, Yan-Ting Jian, Xue-Qing Chen

Open access · hybridAbstract readClinical TrialRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in World journal of gastroenterology, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers, 12 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
64citing papers in PubMed, 12 pooled it
15.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

64 citing papers in PubMed, 12 syntheses or guidelines pooled it, 205 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Probiotics for induction of remission in ulcerative colitis.The Cochrane database of systematic reviews · 2020
    Pooled it
  6. Probiotics for maintenance of remission in ulcerative colitis.The Cochrane database of systematic reviews · 2020
    Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Trial
  14. Effects of synbiotic therapy in mild-to-moderately active ulcerative colitis: A randomized placebo-controlled study.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2019
    Trial
  15. Trial
  16. Trial
  17. Review
  18. Review
  19. Review
  20. Review

4 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Hai-Hong CuiDepartment of Gastroenterology, Chinese PLA Institute of Digestion Medicine, First Military Medical University, Guangzhou 510515, Guangdong Province, China.
Cun-Long Chen
Ji-De Wang
Yu-Jie Yang
Yong Cun
Jin-Bao Wu
Yu-Hu Liu
Han-Lei Dan
Yan-Ting Jian
Xue-Qing Chen
Chinese People's Liberation Army · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimTo investigate the effects of probiotic on intestinal mucosae of patients with ulcerative colitis (UC), and to evaluate the role of probiotic in preventing the relapse of UC.

methodsThirty patients received treatment with sulphasalazine (SASP) and glucocorticoid and then were randomly administered bifid triple viable capsule (BIFICO) (1.26 g/d), or an identical placebo (starch) for 8 wk. Fecal samples were collected for stool culture 2 wk before and after the randomized treatments. The patients were evaluated clinically, endoscopically and histologically after 2 mo of treatment or in case of relapse of UC. p65 and IkappaB expressions were determined by Western blot analysis. DNA-binding activity of NF-kappaB in colonic nuclear extracts was detected by electrophoretic mobility shift assay (EMSA). mRNA expressions of cytokines were identified by semi-quantitative assay, reverse transcriptase- polymerase chain reaction (RT-PCR).

resultsThree patients (20%) in the BIFICO group had relapses during 2-mo follow-up period, compared with 14 (93.3%) in placebo group (P<0.01). The concentration of fecal lactobacilli, bifidobacteria was significantly increased in BIFICO-treated group only (P<0.01). The expressions of NF-kappaB p65 and DNA binding activity of NF-kappaB were significantly attenuated in the treatment group than that in control (P<0.05). The mRNA expression of anti-inflammatory cytokines was elevated in comparison with the control group.

conclusionThe probiotic could impede the activation of NF-kappaB, decrease the expressions of TNF-alpha and IL-1beta and elevate the expression of IL-10. These results suggest that oral administration of this new probiotic preparation is effective in preventing flare-ups of chronic UC. It may become a prophylactic drug to decrease the relapse of UC.

Indexed as

Anti-Inflammatory Agents, Non-SteroidalCell NucleusColitis, UlcerativeFecesGlucocorticoidsHumansI-kappa B ProteinsInterleukin-1Interleukin-10Intestinal MucosaNF-kappa BProbioticsRetrospective StudiesSulfasalazineTumor Necrosis Factor-alphaAnti-Inflammatory Agents, Non-SteroidalGlucocorticoidsI-kappa B ProteinsInterleukin-1Interleukin-10NF-kappa BSulfasalazineTumor Necrosis Factor-alpha

Identifiers

PMID15133865
PMCPMC4656296
OpenAlexW1583799593

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.